Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,095.98 +31.94 (+3.00%)

Streaming Delayed Price Updated: 9:38 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

My Top 5 Stocks to Buy in Early 2026 ↗

Today 4:35 EST

These companies are leaders in their fields.

Via The Motley Fool

Topics Artificial Intelligence

Ventyx (VTYX) Shares Soar 62.5% Overnight, Here's What's Going On With This Trending Stock ↗

January 06, 2026

Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion.

Via Benzinga

Eli Lilly Stock Rises After Hours On UBS ‘Buy’ Call Ahead Of Oral Obesity Pill Launch — GLP-1 Battle With Novo Heats Up ↗

January 06, 2026

Via Stocktwits

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

January 06, 2026

Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.

Via The Motley Fool

Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’ ↗

January 05, 2026

Via Stocktwits

Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial? ↗

January 06, 2026

Novo Nordisk has some good GLP-1 news, but is the company's failed Alzheimer's trial a long-term problem?

Via The Motley Fool

Topics Intellectual Property

Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover ↗

January 06, 2026

Shares of Ventyx Biosciences launched late Tuesday on reports Eli Lilly could be nearing a $1 billion deal to buy the company.

Via Investor's Business Daily

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

Via MarketMinute

Topics Economy

S&P 500 Shatters Records: Index Crosses 6,944 as Tech Giants and Healthcare Titans Lead the Charge

January 06, 2026

The S&P 500 reached a historic milestone on January 6, 2026, closing at a new all-time high of 6,944.82. This 0.6% gain on the first full trading week of the year signals a powerful continuation of the...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Ventyx Biosciences Stock Jumps On Reports Of Eli Lilly Buyout ↗

January 06, 2026

A deal for Ventyx could be announced imminently, the Wall Street Journal reported, citing people familiar with the matter.

Via Stocktwits

Eli Lilly Inks Deal With Nimbus Therapeutics To Find New Obesity Drug With AI ↗

January 06, 2026

Under the deal, Nimbus is eligible to receive up to $1.3 billion.

Via Stocktwits

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

January 06, 2026

As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy Government

The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall

January 06, 2026

As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value? ↗

January 06, 2026

Eli Lilly offers investors safety and growth.

Via The Motley Fool

Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss ↗

January 06, 2026

Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.

Via Investor's Business Daily

Motley Fool Money: Stock Market Naughty and Nice List ↗

January 06, 2026

There were nice companies and great CEOs in 2025, but also some duds. We discuss the stocks on each list and end by going shopping for stocks.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown? ↗

January 06, 2026

Several clinical readouts and regulatory decisions are scheduled for Eli Lilly in 2026.

Via Stocktwits

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Via Stocktwits

2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore

January 05, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Prediction: The S&P 500 $1 Trillion Club Will Double Between 2026 and 2030 ↗

January 05, 2026

Several companies could see massive gains by 2030 to join the vaunted club.

Via The Motley Fool

Topics Stocks

The 2026 Blueprint: Five Core Stocks to Anchor Your Portfolio in a Year of AI Realization

January 05, 2026

As we cross the threshold into 2026, the financial markets have entered a sophisticated new phase. The "AI Gold Rush" of 2024 and 2025 has matured into what analysts are calling the "Era of AI...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Should Investors Be Worried That the "Magnificent Seven" Make Up 35% of the S&P 500? ↗

January 05, 2026

At the very least, investors should be concerned. There's a way to avoid the problem, though.

Via The Motley Fool

Topics Stocks

Top S&P500 movers in Monday's session ↗

January 05, 2026

Via Chartmill

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

January 05, 2026

Via MarketBeat

Topics Artificial Intelligence Death

Bank of America Issues 2026 'Priced for Perfection' Warning: Why the S&P 500 Faces a High-Stakes 'Air Pocket'

January 05, 2026

As the financial world rings in 2026, a sobering forecast from one of Wall Street’s most influential institutions has sent a ripple of caution through the markets. Bank of America (NYSE: BAC) Global...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Priced for Perfection: Bank of America Issues Stark Warning on S&P 500 Valuation for 2026

January 05, 2026

As the calendar turns to 2026, the euphoria that propelled the stock market through three consecutive years of double-digit gains is facing a sobering reality check. Bank of America (NYSE: BAC) has...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever ↗

January 05, 2026

Via MarketBeat

Eli Lilly: Strength Meets GLP‑1 Access Momentum ↗

January 05, 2026

Eli Lilly's stock remains robust at $1,080.36 amid positive market developments, strong GLP-1 access momentum, and heightened investor interest ahead of key earnings announcements.

Via Talk Markets

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 05, 2026

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Via The Motley Fool

January 04, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.